- Colony-stimulating Factor
- Interferon
- Erythropoietin
- Other Protein Types
PEGylated Proteins Market size was valued at USD 1.2 billion in 2023 and is poised to grow at 11.9% CAGR over the forecast years to reach USD 2.6 billion by 2030. The PEGylated proteins market refers to the sector involved in the development, production, and distribution of proteins that have been modified through a process called PEGylation. PEGylation involves attaching polyethylene glycol (PEG) chains to proteins. This modification can enhance the therapeutic properties of proteins by increasing their stability, prolonging their half-life in the body, reducing immunogenicity (the likelihood of causing an immune response), and improving their solubility and overall pharmacokinetic profile. These applications span a wide range of medical fields, including oncology, hematology, immunology, and other areas where protein-based therapies are utilized. The growth of the PEGylated proteins market is primarily driven by several key factors. One major factor is the increasing prevalence of chronic diseases such as cancer, kidney diseases, and rheumatoid arthritis.
Moreover, globally, diseases like HIV, tuberculosis, and others contribute to the growing burden of chronic and infectious diseases. This rising disease burden is expected to increase the demand for innovative medicines, thereby boosting research and development efforts focused on proteins, including PEGylated proteins. Furthermore, biotechnology and pharmaceutical companies are increasingly investing in research and development programs. For instance, in March 2022, Flow Eighteen38, a division focused on protein sciences, announced a substantial investment into its protein production and characterization capabilities. Such investments are crucial for advancing protein-based therapies, including PEGylated proteins. Additionally, the adoption of protein-based drugs over non-protein-based drugs is on the rise. PEGylation plays a vital role in this trend by enhancing the circulation and half-life of proteins, thereby improving their efficacy and making them more attractive for therapeutic use. However, key factors hampering the growth of the global PEGylated proteins market include complex and costly development processes, regulatory challenges in proving safety and efficacy, and concerns over immunogenicity and long-term effects, amidst increasing competition from alternative therapies and potential manufacturing scalability issues.
Study Period
Base Year
CAGR
Largest Market
Fastest Growing Market
The PEGylated proteins market is projected to grow driven by factors such as the expanding biologics industry, increasing adoption of protein-based drugs over non-protein alternatives, and the rising incidence of lifestyle-related illnesses. This includes chronic diseases like cancer, kidney disease, and rheumatoid arthritis, with chronic kidney disease affecting approximately 15% of American adults, according to the CDC's 2021 report. There is a current focus on developing new therapies using PEGylated proteins to address chronic renal conditions, leveraging PEGylation to enhance protein circulation, half-life, and therapeutic effectiveness. According to GLOBOCAN 2020, there were 19,292,789 new cancer cases diagnosed globally in 2020, leading to 9,958,133 cancer-related deaths. Breast cancer accounted for 2,261,419 new cases, lung cancer for 2,206,771, prostate cancer for 1,414,259, and colon cancer for 1,148,515. Additionally, as per the UNAIDS Global HIV and AIDS Statistics 2021, 37.7 million people worldwide were living with HIV in 2020. The increasing global burden of chronic and infectious diseases such as cancer, HIV, and tuberculosis is expected to drive demand for medical advancements.
The global PEGylated proteins market was valued at USD 1.2 billion in 2023 and is projected to grow at 11.9% CAGR over the forecast years to reach USD 2.6 billion by 2030.
The global PEGylated proteins market is segmented based on protein type, end-users, and geography.
The key players in the PEGylated proteins market are Thermo Fisher Scientific Inc., Merck KGaA, NOF CORPORATION, Jenkem Technology USA, Celares GmbH, Creative PEGWorks, Quanta BioDesign, Ltd., Layson Bio Inc., Iris Biotech Gmbh, Life Diagnostics, Enzon Pharamaceuticals, Inc., and Takeda Pharmaceuticals Company Limited.
Key drivers for the PEGylated proteins market include the rising prevalence of chronic diseases necessitating effective therapies, PEGylation's enhancement of protein stability and efficacy, and robust growth in the biologics sector supported by technological advancements and favourable regulatory environments.
Key factors hampering the global PEGylated proteins market include complex and costly development processes, stringent regulatory requirements, concerns over immunogenicity and long-term safety, competition from alternative therapies like ADCs and gene therapies, and challenges in scaling up manufacturing while ensuring consistency and quality.
1.Executive Summary |
2.Global PEGylated Proteins Market Introduction |
2.1.Global PEGylated Proteins Market - Taxonomy |
2.2.Global PEGylated Proteins Market - Definitions |
2.2.1.Protein Type |
2.2.2.End User |
2.2.3.Region |
3.Global PEGylated Proteins Market Dynamics |
3.1. Drivers |
3.2. Restraints |
3.3. Opportunities/Unmet Needs of the Market |
3.4. Trends |
3.5. Product Landscape |
3.6. New Product Launches |
3.7. Impact of COVID 19 on Market |
4.Global PEGylated Proteins Market Analysis, 2019 - 2023 and Forecast 2024 - 2030 |
4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) |
4.3. Market Opportunity Analysis |
5.Global PEGylated Proteins Market By Protein Type, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
5.1. Colony-stimulating Factor |
5.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.1.3. Market Opportunity Analysis |
5.2. Interferon |
5.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.2.3. Market Opportunity Analysis |
5.3. Erythropoietin |
5.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
5.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.3.3. Market Opportunity Analysis |
5.4. Other Protein Types |
5.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
5.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.4.3. Market Opportunity Analysis |
6.Global PEGylated Proteins Market By End User, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
6.1. Pharmaceutical and Biotechnology Companies |
6.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.1.3. Market Opportunity Analysis |
6.2. Contract Research Organizations |
6.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.2.3. Market Opportunity Analysis |
6.3. Academic Research Institutes |
6.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
6.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.3.3. Market Opportunity Analysis |
7.Global PEGylated Proteins Market By Region, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
7.1. North America |
7.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.1.3. Market Opportunity Analysis |
7.2. Europe |
7.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.2.3. Market Opportunity Analysis |
7.3. Asia Pacific (APAC) |
7.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.3.3. Market Opportunity Analysis |
7.4. Middle East and Africa (MEA) |
7.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
7.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.4.3. Market Opportunity Analysis |
7.5. Latin America |
7.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
7.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.5.3. Market Opportunity Analysis |
8.North America PEGylated Proteins Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
8.1. Protein Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
8.1.1.Colony-stimulating Factor |
8.1.2.Interferon |
8.1.3.Erythropoietin |
8.1.4.Other Protein Types |
8.2. End User Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
8.2.1.Pharmaceutical and Biotechnology Companies |
8.2.2.Contract Research Organizations |
8.2.3.Academic Research Institutes |
8.3. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
8.3.1.United States of America (USA) |
8.3.2.Canada |
9.Europe PEGylated Proteins Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
9.1. Protein Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
9.1.1.Colony-stimulating Factor |
9.1.2.Interferon |
9.1.3.Erythropoietin |
9.1.4.Other Protein Types |
9.2. End User Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
9.2.1.Pharmaceutical and Biotechnology Companies |
9.2.2.Contract Research Organizations |
9.2.3.Academic Research Institutes |
9.3. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
9.3.1.Germany |
9.3.2.France |
9.3.3.Italy |
9.3.4.United Kingdom (UK) |
9.3.5.Spain |
10.Asia Pacific (APAC) PEGylated Proteins Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
10.1. Protein Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.1.1.Colony-stimulating Factor |
10.1.2.Interferon |
10.1.3.Erythropoietin |
10.1.4.Other Protein Types |
10.2. End User Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.2.1.Pharmaceutical and Biotechnology Companies |
10.2.2.Contract Research Organizations |
10.2.3.Academic Research Institutes |
10.3. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.3.1.China |
10.3.2.India |
10.3.3.Australia and New Zealand (ANZ) |
10.3.4.Japan |
10.3.5.Rest of APAC |
11.Middle East and Africa (MEA) PEGylated Proteins Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
11.1. Protein Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.1.1.Colony-stimulating Factor |
11.1.2.Interferon |
11.1.3.Erythropoietin |
11.1.4.Other Protein Types |
11.2. End User Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.2.1.Pharmaceutical and Biotechnology Companies |
11.2.2.Contract Research Organizations |
11.2.3.Academic Research Institutes |
11.3. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.3.1.GCC Countries |
11.3.2.South Africa |
11.3.3.Rest of MEA |
12.Latin America PEGylated Proteins Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
12.1. Protein Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.1.1.Colony-stimulating Factor |
12.1.2.Interferon |
12.1.3.Erythropoietin |
12.1.4.Other Protein Types |
12.2. End User Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.2.1.Pharmaceutical and Biotechnology Companies |
12.2.2.Contract Research Organizations |
12.2.3.Academic Research Institutes |
12.3. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.3.1.Brazil |
12.3.2.Mexico |
12.3.3.Rest of LA |
13. Competition Landscape |
13.1. Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) |
13.2.1.Thermo Fisher Scientific Inc. |
13.2.2.Merck KGaA |
13.2.3.NOF CORPORATION |
13.2.4.Jenkem Technology USA |
13.2.5.Celares GmbH |
13.2.6.Creative PEGWorks |
13.2.7.Quanta BioDesign, Ltd. |
13.2.8.Layson Bio Inc. |
13.2.9.Iris Biotech Gmbh |
13.2.10.Life Diagnostics |
13.2.11.Enzon Pharamaceuticals, Inc. |
13.2.12.Takeda Pharmaceuticals Company Limited |
14. Research Methodology |
15. Appendix and Abbreviations |